What is Ossum D?
Ossum D is a medicine that increases the movements or contractions of the stomach and bowel. Ossum D is also used to treat nausea and vomiting caused by other drugs used to treat Parkinson's Disease.
Ossum D is to be given only by or under the immediate supervision of your doctor.
Ossum D indications
Dyspeptic symptom complex often associated with delayed gastric emptying, gastroesophageal reflux disease (GERD) or esophagitis: Epigastric sense of fullness, feeling of abdominal distention, upper abdominal pain, flatulence (gassiness), eructation (belching), and heartburn.
Short-term treatment of nausea and vomiting of various origins including functional, organic, infectious, diabetic origin, or induced by radiotherapy or medicine therapy. (It is not considered suitable for chronic nausea and vomiting, nor for the routine prophylaxis of postoperative vomiting.)
Treatment of nausea and vomiting induced by dopamine agonists ie, L-dopa and bromocriptine used in Parkinson's disease.
Ossum D may also be given as needed, together with paracetamol for the symptomatic treatment of nausea and vomiting associated with migraine.
Uses of Ossum D in details
Ossum D is used to treat vomiting or nausea caused due to indigestion, diseases or drugs. It is also used to relieve fullness of stomach, belching and heavy bloating, gas and heartburn for a longer period up to 2 weeks.
Ossum D description
Ossum D is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K mediated gamma-carboxylation of precursor proteins.
Ossum D dosage
It is recommended to take oral Ossum D before meals. If taken after meals, absorption of the drug is somewhat delayed.
Adults and Adolescents >12 years and weighing ≥35 kg: Tablets: One to two 10-mg tablet 3-4 times/day, with a maximum daily dose of 8 tablets (80 mg).
Oral Suspension:
10-20 mL (of oral susp containing Ossum D 1 mg/mL) 3-4 times/day, with a maximum daily dose of 80 mL.Infants and Children: 0.25-0.5 mg/kg 3-4 times/day with a maximum daily dose of 2.4 mg/kg (but do not exceed 80 mg/day).
Tablets are unsuitable for use in children weighing <35 kg.
Oral Suspension:
0.25-0.5 mg/kg 3-4 times/day with a maximum dose of 2.4 mg/kg (not exceeding 80 mL).Ossum D interactions
The concomitant administration of Ossum D with phenothiazines, butyrophenones and rauwolfia alkaloids may induce the endocrine disturbances or extrapyramidal disorders. If necessary, monitored carefully and administered cautiously.
Should be administered cautiously in patients receiving digitalis preparations.
The concomitant administration of Ossum D with anticholinergic agents may compromise the beneficial effects of Ossum D because of depressing the promoting action of gastrointestinal motility.
Theologically, Ossum D may have an effect on the absorption of oral preparations, especially slow-releasing or enteric-coated preparations because of increasing gastric motility. But in patients stabilized with digoxin or acetaminophen, the concomitant administration of Ossum D had no effect on plasma concentration of these drugs.
It is not reported that Ossum D enhances the effect of neuroleptics.
Ossum D inhibits peripheral adverse reactions eg, dyspepsia, nausea, vomiting, induced by dopamine agonist (eg, bromocriptine, levodopa), but has no effect on central nervous system.
As the concomitant administration of Ossum D with antacids or acid secretion inhibitors lowers biologic activity of Ossum D, these drugs should not be used together.
The actions of Ossum D on gastrointestinal function may be antagonised by antimuscarinics and opioid analgesics.
Ossum D side effects
See also:
What are the possible side effects of Ossum D?
Clinical Trial Data: The safety of Ossum D was evaluated in 1221 patients with gastroparesis, dyspepsia, gastro-oesophageal reflux disorder (GERD) or other related conditions in 45 clinical trials included in the safety database. All patients were ≥15 years and received at least 1 dose of oral Ossum D (Ossum D base). Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10-160 mg), with 230 patients receiving a dose >80 mg. Median duration of exposure was 56 days (range 1-2248 days).
Adverse drug reactions (ADRs) reported by ≥1% of patients treated with oral Ossum D in these 45 clinical trials (n=1221) are the following: Psychiatric Disorders: Depression (2.5%), anxiety (1.6%), decreased libido/loss of libido (1.5%).
Nervous System Disorders: Headache (5.6%), somnolence (2.5%), akathisia (1%).
Gastrointestinal Disorders: Diarrhoea (5.2%).
Skin and Subcutaneous Tissue Disorders: Rash (2.8%), pruritus (1.7%).
Reproductive System and Breast Disorders: Breast enlargement/gynaecomastia (5.3%), breast tenderness (4.4%), galactorrhoea (3.3%), amenorrhoea (2.9%), breast pain (2.3%), irregular menstruation (2%), lactation disorder (1.6%).
General Disorders and Administration Site Conditions: Asthenia (1.9%).
ADRs that occurred in <1% of Ossum D-treated patients in the 45 clinical trials (n=1221) are the following: Immune System Disorders: Hypersensitivity (0.2%).
Skin and Subcutaneous Disorders: Urticaria (0.7%).
Reproductive System and Breast Disorders: Breast discharge (0.8%), breast swelling (0.5%).
Dry mouth has been reported with over-the-counter use of Ossum D.
Post-Marketing: In addition to the adverse effects reported during clinical studies and previously mentioned, the following adverse drug reactions provided the frequencies according to the following convention: Very common (≥1/10), common (≥1/100 and <1/10); uncommon (≥1/1000 and <1/100); rare (≥1/10,000 and <1/1000); very rare (<1/10,000, including isolated reports).
The following ADRs are presented by frequency category based on spontaneous reporting rates: Immune System Disorders: Very Rare: Anaphylactic reactions (including anaphylactic shock).
Psychiatric Disorders: Very Rare: Agitation, nervousness.
Nervous System Disorders: Very Rare: Extrapyramidal disorder, convulsion.
Cardiac Disorders: Very Rare: Sudden cardiac death*, serious ventricular arrhythmias*.
Skin and Subcutaneous Tissue Disorders: Very Rare: Angioedema.
Renal and Urinary Disorders: Very Rare: Urinary retention.
Investigations: Very Rare: Abnormal liver function test; increased blood prolactin.
Note: *Based on epidemiology data (as follows).
As the hypophysis is outside the blood-brain barrier, Ossum D may cause an increase in prolactin levels. In rare cases, this hyperprolactinaemia may lead to neuro-endocrinological side effects eg, galactorrhoea, gynaecomastia and amenorrhoea.
Extrapyramidal disorder occurs primarily in neonates and infants.
Other central nervous system-related effects of convulsion and agitation are also reported primarily in infants and children.
An increase in the risk of serious ventricular arrhythmias and sudden cardiac death has been reported in some epidemiology studies. Due to the limitations of these data, risk factors and the exact frequency of these adverse reactions could not be defined.
Ossum D contraindications
Hypersensitivity to Ossum D or any ingredient of Ossum D.
If patients are taking oral ketoconazole, fluconazole, voriconazole, erythromycin, clarithromycin, telithromycin, amiodarone, selective serotonin reuptake inhibitors, HIV protease inhibitors, calcium antagonists which can increase plasma concentrations of Ossum D, leading to a prolonged QTc interval. These medicines can increase plasma concentrations of Ossum D leading to a prolonged QTc interval. Patients with long QT syndrome develop a very fast heart rhythm disturbance leading to a sudden loss of consciousness.
Gastrointestinal hemorrhage (bleeding), obstruction, perforation or conditions where gastrointestinal stimulation or movements may be dangerous.
Prolactin-releasing pituitary tumor (prolactinoma).
Active ingredient matches for Ossum D:
| Unit description / dosage (Manufacturer) | Price, USD |
| Ossum D 20+10 Capsule | $ 0.07 |
List of Ossum D substitutes (brand and generic names): | |
| Ospicid D | |
| Ospicid D 20+10 Tablet (Auspi Medicaments) | $ 0.06 |
| Osteocid D | |
| Osteocid D 20+30 Capsule (Wanbury Ltd.) | $ 0.10 |
| OSTEOCID D 30 MG/20 MG CAPSULE 1 strip / 10 capsules each (Wanbury Ltd.) | $ 1.25 |
| OTRON-D (India) | |
| 10 mg x 10's (Daffohils) | |
| Otron-D 10mg MD-TAB / 10 (Daffohils) | |
| OTRON-D MD- tab 10 mg x 10's (Daffohils) | |
| Otron-D 10mg MD-TAB / 10 (Daffohils) | |
| Otto D | |
| Otto D 20+10 Capsule (Pharmacon Gignos) | $ 0.07 |
| Oysirab DM | |
| Oysirab DM 20+10 Tablet (Oyster Labs Limited) | $ 0.07 |
| OZ 20 D | |
| OZ 20 D 20+10 Capsule (Bindlysh Biotech Ltd) | $ 0.05 |
| Ozad D | |
| Ozad D 20+10 Capsule (Doff Biotech (P) Ltd.) | $ 0.05 |
| Oze D | |
| Oze D 20+10 Capsule (Medix Laboratories (I) Pvt. Ltd.) | $ 0.06 |
| Ozed D | |
| Ozed D 20+10 Capsule (Biosans Lifecare) | $ 0.07 |
| Ozidom | |
| Ozidom 20+10 Tablet (Sanbury Healthcare (P) Ltd) | $ 0.05 |
| Ozodon | |
| Ozodon 20+10 Capsule (Chemo Biological) | $ 0.05 |
| Ozol D | |
| Ozol D 20+10 Tablet (N.B. Healthcare) | $ 0.05 |
| OZOL D 10MG/20MG CAPSULE 1 strip / 10 capsules each (N.B. Healthcare) | $ 0.54 |
| Ozol D Capsule (N.B. Healthcare) | $ 0.05 |
| Ozone DM | |
| Ozone DM 20+10 Tablet (United Labs) | $ 0.06 |
| OZZ D | |
| OZZ D 20+10 Capsule (Prism Pharma) | $ 0.05 |
| Panpac-DSR (India) | |
| Panpac-DSR Pantoprazole / EC40mg, Domperidone / SR30mg TAB / 10 (Acto) | $ 0.78 |
| 10's (Acto) | $ 0.78 |
| PANPAC-DSR tab 10's (Acto) | $ 0.78 |
| Paridon (Bangladesh) | |
| PARIDON 40 MG TABLET 1 strip / 10 tablets each (Symbiosis Lab) | $ 0.49 |
| Paridon 40mg Tablet (Symbiosis Lab) | $ 0.05 |
| Passagix (Russian Federation) | |
| Tablet, Film-Coated; Oral; Domperidone 10 mg (Obolenskoe) | |
| Pedomcad (Vietnam) | |
| Pedomcad 10 mg x 10 Blister x 1 Tablet | |
| Pedomcad suspension (Vietnam) | |
| Pedomcad suspension 1 mg/1 mL x 1 Bottle thuГ»y tinh 30mL | |
| Pelidone (Taiwan) | |
| Pelidone 10 mg | |
| Pepridon (Philippines) | |
| Pepridon 10 mg x 100's | $ 32.00 |
| Peptomet (Cyprus, Kenya, Sudan, Taiwan, Zimbabwe) | |
| Peptomet 10 mg x 20's (Remedica) | |
| Peptomet 10 mg x 1000's (Remedica) | |
| Peptomet 10 mg x 1's (Remedica) | |
| Peridal (Brazil) | |
| Peridom (Thailand, Vietnam) | |
| PERIDOM 1MG SUSPENSION 1 bottle / 50 ML suspension each (Wens Drugs India Pvt Ltd) | $ 0.42 |
| PERIDOM 1MG TABLET 1 strip / 10 tablets each (Wens Drugs India Pvt Ltd) | $ 1.55 |
| Peridom 1mg Suspension (Wens Drugs India Pvt Ltd) | $ 0.42 |
| Peridom 1mg Tablet (Wens Drugs India Pvt Ltd) | $ 0.15 |
| Peridom 10mg (Oman) | |
| Peridom-M (Thailand) | |
| Peridom-M 10 mg x 50 x 10's (Masa) | |
| Peridom-M 10 mg x 1, 000's (Masa) | |
| Peridom-M 10 mg x 10 Blister x 10 Tablet (Masa) | |
See 2682 substitutes for Ossum D | |
References
- PubChem. "domperidone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "domperidone". http://www.drugbank.ca/drugs/DB01184 (accessed September 17, 2018).
- DTP/NCI. "domperidone: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Ossum D are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ossum D. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
